NEW ORLEANS--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), today announced that data from clinical trials of vilazodone, a novel investigational compound for the treatment of major depressive disorder (MDD), as well as preclinical data characterizing its mechanism of action, will be presented at the annual meetings of the American Psychiatric Association (APA) and the Society of Biological Psychiatry (SOBP). The presentations include positive results from the second placebo-controlled Phase III clinical trial of vilazodone, a long-term safety study, and findings from nonclinical studies supporting the potential benefits of vilazodone’s unique mechanism of action. The Company’s New Drug Application (NDA) for vilazodone for the treatment of MDD was accepted by the U.S. Food and Drug Administration (FDA) for filing and is currently under review.
